Benzinga’s Top Pre-Market NASDAQ Losers (IMGN, OVTI, NOVL, ARMH)

ImmunoGen Inc IMGN dipped 23.12% to $6.45 in the pre-market session. IMGN has received a Refuse to File (RTF) letter from the FDA for its breast cancer treatment. OmniVision Technologies Inc OVTI lost 2.85% to $21.50 in the pre-market session. OVTI had reported weaker-than-expected Q1 revenue. Novell Inc NOVL fell 2.30% to $5.51 in the pre-market session. NOVL had posted weaker-than-expected FQ3 results. ARM Holdings Plc ARMH slipped 0.91% to $15.29 in pre-market trading. ARMH’s earnings are likely to fall by 8.26% this year. Read more from Benzinga's Company news.